Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple oxygen device prevent breathing trouble in obese patients during endoscopy?

NCT ID NCT06585306

Disease control Sponsor: XiaoLiang Wang Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 28, 2026 · Last updated Aug 28, 2026

Summary

Obese patients often have extra tissue in the airway and reduced lung capacity, making them prone to low oxygen levels during sedated endoscopy. This trial tests high-flow nasal oxygen at three flow rates, 30, 50, and 70 liters per minute, to see which best prevents hypoxia. Researchers will enroll 864 obese adults undergoing sedative gastrointestinal endoscopy and compare the rates of oxygen drops and related complications. The goal is to find the safest and most comfortable oxygen setting for this common procedure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
High-flow nasal oxygen therapy at three flow rates (30, 50, and 70 L/min)
What this could lead to
If it works, this could identify the best oxygen flow rate to prevent dangerous drops in blood oxygen during sedative endoscopy in obese patients, improving safety for a common procedure.
What could go wrong
The trial is early and focuses on a specific patient group, so results may not apply broadly. Higher flow rates may cause nasal discomfort, and the optimal rate may vary by individual.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

864 people

The number who actually took part.

Started

Oct 2024

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients undergoing sedative gastrointestinal endoscopy 2. Aged over 18. 3. ASA classification I-III 4. BMI\>28kg/m2 5. Compliance with ethics, patient willing to participate in the trial, signed informed consent form Exclusion Criteria: 1. Contraindications for endoscopic procedures or patients refusing sedation/anesthesia. 2. Patients with allergies to propofol, eggs, soybeans, or milk. 3. Patients with gastrointestinal obstruction and gastric emptying disorders. 4. Patients with acute pharyngitis, tonsillitis, and upper respiratory tract infections. 5: Patients with acute exacerbations of respiratory diseases such as asthma, bronchitis, and COPD. 6. Patients with acute arrhythmias and severe heart disease (congenital, valvular disease). 7. Patients requiring replacement therapy for severe liver or kidney dysfunction. 8\. Patients with severe mental illnesses requiring medication to control symptoms. 9\. Patients with moderate to severe anemia, coagulation disorders, and hematological diseases. 10. Patients with severe nasal congestion caused by nasal cavity lesions. 11. Pregnant and lactating patients.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastrostomy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hypoxia Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastrostomy Hypoxia Obesity

Contacts and locations

Locations

  • Nanjing First Hospital

    Nanjing, Jiangsu, 210006, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.